

Supplementary Table S7. Baseline comparison between b/tsDMARD non-naïve and naïve RA cohorts initiating JAKi or TNFi.

A. JAKi cohorts: Cohort 2 (non-naïve) vs Cohort 3 (naïve)

Baseline characteristic	Cohort 2 Non-naïve JAKi (n=32)	Cohort 3 Naïve JAKi (n=36)	p-value
Disease evolution, years (mean ± SD)	13.81 ± 9.55	10.90 ± 10.01	0.226
DAS28-CRP (mean ± SD)	4.20 ± 0.85	4.59 ± 1.13	0.116
SDAI (mean ± SD)	22.63 ± 7.37	26.80 ± 12.80	0.110
CDAI (mean ± SD)	21.34 ± 7.03	25.82 ± 12.38	0.076
CRP, mg/mL (mean ± SD)	12.86 ± 15.03	9.80 ± 11.66	0.349
ESR, mm/h (mean ± SD)	29.97 ± 19.75	23.02 ± 27.67	0.243
Smoking (n, %)	10/32 (31.3%)	11/36 (30.6%)	1.000
Hypertension (n, %)	6/32 (18.8%)	8/36 (22.2%)	0.772
Corticosteroids (n, %)	25/32 (78.1%)	27/36 (75.0%)	0.783
cDMARDs (n, %)	24/32 (75.0%)	28/36 (77.8%)	1.000

Prior b/tsDMARD exposure: Cohort 2: TNFi 18/32 (56.3%), IL-6Ri 5/32 (15.6%), JAKi 7/32 (21.9%), CTLA-4 1/32 (3.1%), anti-CD20 1/32 (3.1%). Cohort 3: none by cohort definition.

B. TNFi cohorts: Cohort 4 (non-naïve) vs Cohort 5 (naïve)

Baseline characteristic	Cohort 4 Non-naïve TNFi (n=30)	Cohort 5 Naïve TNFi (n=125)	p-value
Disease evolution, years (mean ± SD)	11.17 ± 8.54	8.77 ± 7.57	0.130
DAS28-CRP (mean ± SD)	4.61 ± 1.02	4.62 ± 1.25	0.968
SDAI (mean ± SD)	27.49 ± 9.75	27.53 ± 13.83	0.988
CDAI (mean ± SD)	26.23 ± 9.44	25.69 ± 12.80	0.828
CRP, mg/mL (mean ± SD)	12.58 ± 18.93	18.39 ± 29.15	0.300
ESR, mm/h (mean ± SD)	20.31 ± 18.30	23.88 ± 22.37	0.419
Smoking (n, %)	9/30 (30.0%)	38/125 (30.4%)	1.000
Hypertension (n, %)	4/30 (13.3%)	28/125 (22.4%)	0.325
Corticosteroids (n, %)	27/30 (90.0%)	98/125 (78.4%)	0.200
cDMARDs (n, %)	23/30 (76.7%)	120/125 (96.0%)	0.002

Prior b/tsDMARD exposure: Cohort 4: TNFi 15/30 (50.0%), IL-6Ri 3/30 (10.0%), JAKi 10/30 (33.3%), CTLA-4 2/30 (6.7%), anti-CD20 0/30 (0%). Cohort 5: none by cohort definition.

Continuous variables were compared using Student's t-test or Mann–Whitney U test, as appropriate. Categorical variables were compared using two-sided Fisher's exact test. DAS28-CRP, Disease Activity Score 28-C-reactive protein; SDAI, Simplified Disease Activity Index; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; cDMARDs, conventional disease-modifying antirheumatic drugs; TNFi,

tumour necrosis factor inhibitor; IL-6Ri, interleukin-6 receptor inhibitor; JAKi, Janus kinase inhibitor; CTLA-4, cytotoxic T-lymphocyte antigen 4.